2021-05-18: New reagent for direct determination of LDL-cholesterol

DiaSys is pleased to announce the availability of LDL-c direct FS, a new homogenous assay for direct determination of LDL-cholesterol (LDL-C). LDL C is used as lipid panel parameter to estimate the risk of developing heart disease and to guide and monitor lipid-lowering therapies. Atherosclerotic cardiovascular disease (ASCVD) starts early in life, often during childhood. Studies revealed that 71% and 43% of middle-aged men and women, respectively, show evidence of subclinical atherosclerosis. Evidence from epidemiologic, genetic, and clinical intervention studies have clearly demonstrated that low-density lipoprotein (LDL) is causal in this process.

LDL-C is often not measured directly but is instead estimated by using the Friedewald equation, which estimates LDL-C from measurements of total cholesterol (TC), triglycerides (TG), and high density lipoprotein cholesterol (HDL-C) but the method only approximates LDL-C and is subject to well-established limitations. Since the introduction of homogeneous methods at the end of the last century, these new methods have become the standard in clinical laboratories.

The new DiaSys assay LDL-c direct FS is characterized by a wide measuring range and shows good overall precision at clinical decision limits. The ready-to-use reagent offers a long stability on board combined with low calibration frequency. The new test may be applied on all automated clinical chemical analyzers and shows good comparability with commercially available methods for the determination of LDL-cholesterol.

The new test is available in different kit concepts. For further information, please follow the link: LDL-c direct FS